- Conditions
- Primary Mediastinal Large B-Cell Lymphoma
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Doxorubicin Hydrochloride, Echocardiography Test, Etoposide Phosphate, Filgrastim, Lumbar Puncture, Nivolumab, Pegfilgrastim, Positron Emission Tomography, Prednisolone, Prednisone, Radiation Therapy, Rituximab, Rituximab and Hyaluronidase Human, Vincristine Sulfate
- Procedure · Drug · Biological + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 2 Years and older
- Enrollment
- 244 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 215
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 162 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 97–120
of 1,913
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Recurrent Langerhans Cell Histiocytosis, Refractory Langerhans Cell Histiocytosis
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Echocardiography Test, FDG-Positron Emission Tomography and Computed Tomography Scan, Lumbar Puncture, Multigated Acquisition Scan, Tovorafenib
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 180 Days to 22 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 107
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 84 more
- Conditions
- Recurrent Multiple Myeloma, Refractory Multiple Myeloma
- Interventions
- Cxcr1/2 Inhibitor SX-682, Daratumumab and Recombinant Human Hyaluronidase, Carfilzomib, Dexamethasone, Biospecimen Collection, Bone Marrow Aspiration, Echocardiography, Positron Emission Tomography, Computed Tomography, Magnetic Resonance Imaging
- Drug · Procedure
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Alzheimer's Disease
- Interventions
- 11C-PIB PET Scan, FDG-PET Scan
- Radiation
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 30 Years to 90 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2021
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Breast Cancer
- Interventions
- PET/MR
- Diagnostic Test
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Schwannomas, Malignant Tumors
- Interventions
- 18F-DCFPyL Injection
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Chronic Pain
- Interventions
- [18F]FDG, PET/MRI
- Drug · Device
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 88 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2022
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- IDH Wild Type Glioblastoma
- Interventions
- ¹⁸F-Fluoromisonidazole, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Oxygen Therapy, Ferumoxytol, Gadolinium
- Drug · Procedure
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2030
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Glioma
- Interventions
- [18F]FMISO-PET with contrast-enhanced MRI
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Rectal Neoplasms
- Interventions
- fludeoxyglucose F 18, positron emission tomography, magnetic resonance imaging, laboratory biomarker analysis
- Radiation · Device · Other
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Recurrent Prostate Carcinoma
- Interventions
- Computed Tomography, Gallium Ga 68-labeled PSMA Ligand Glu-urea-Lys(Ahx), Magnetic Resonance Imaging, Positron Emission Tomography
- Procedure · Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Cancer
- Interventions
- PET scanning in cancer
- Other
- Lead sponsor
- American College of Radiology Imaging Network
- Network
- Eligibility
- Not listed
- Enrollment
- 333,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2021
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Mild Cognitive Impairment, Alzheimer's Disease, Alzheimer's Disease, Early Onset, Memory Loss, Memory Disorders, Memory Impairment
- Interventions
- Biomarker Data Collection, MK6240
- Other · Radiation
- Lead sponsor
- GAP Innovations, PBC
- Industry
- Eligibility
- 60 Years to 90 Years
- Enrollment
- 1,200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2028
- U.S. locations
- 22
- States / cities
- Atlantis, Florida • Aventura, Florida • Clermont, Florida + 19 more
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- 18F-fluciclovine PET Scan
- Drug
- Lead sponsor
- Tulane University
- Other
- Eligibility
- 18 Years to 18 Years · Male only
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- New Orleans, Louisiana
- Conditions
- Diffuse Large B Cell Lymphoma
- Interventions
- Thiotepa, Carmustine, Autologous Stem Cell Transplant, Anthracycline-based induction chemotherapy
- Drug · Procedure
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8, Locally Advanced Merkel Cell Carcinoma, Metastatic Merkel Cell Carcinoma, Refractory Merkel Cell Carcinoma, Unresectable Merkel Cell Carcinoma
- Interventions
- Avelumab, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Tuvusertib
- Drug · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 50
- States / cities
- Irvine, California • La Jolla, California • Los Angeles, California + 39 more
- Conditions
- Glioma
- Interventions
- 18F-fluciclovine
- Drug
- Lead sponsor
- James Mountz
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Major Depressive Disorder
- Interventions
- Escitalopram, Aripiprazole, Placebo Capsule, Placebo Tablet
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Cryopyrin-Associated Periodic Syndromes, Amyloidosis
- Interventions
- 124I AT-01
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Pain, Low Back Pain, Leg Pain
- Interventions
- Precision Spinal Cord Stimulation and PET Scan
- Other
- Lead sponsor
- Boston Scientific Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
- Interventions
- Genetic testing, Valemetostat Tosylate, Magnetic Resonance Imaging, Computed Tomography, Bone scan, FDG-Positron Emission Tomography, PSMA PET Scan, Biospecimen Collection, Carboplatin, Cabazitaxel, Abiraterone Acetate, Enzalutamide, Lutetium Lu 177 Vipivotide Tetraxetan
- Other · Drug · Procedure
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 474 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2034
- U.S. locations
- 108
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Chico, California + 91 more
- Conditions
- Intracranial Neoplasm, Low Grade Glioma, Recurrent Glioblastoma, Recurrent World Health Organization (WHO) Grade II Glioma, Recurrent WHO Grade III Glioma
- Interventions
- F-18 Fluoroethyltyrosine (FET), Positron Emission Tomography (PET)
- Drug · Procedure
- Lead sponsor
- Thomas Hope
- Other
- Eligibility
- 3 Years and older
- Enrollment
- 143 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Diabetes, Gastroparesis With Diabetes Mellitus
- Interventions
- PET/CT Scan with 11C-ER176, Core biopsy of gastric muscle
- Drug · Diagnostic Test
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 70 Years · Female only
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Alzheimer Disease, Cognition Disorders
- Interventions
- florbetapir F 18 PET scan
- Drug
- Lead sponsor
- Avid Radiopharmaceuticals
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 317 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 75
- States / cities
- Glendale, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 62 more